(AMLX) – StreetInsider.com Reports
-
Mizuho Downgrades Amylyx Pharmaceuticals inc. (AMLX) to Neutral
-
Amylyx Pharmaceuticals (AMLX) Appoints Bernhardt Zeiher to its Board
-
Amylyx Pharmaceuticals inc. (AMLX) PT Lowered to $8 at H.C. Wainwright
-
Amylyx Pharmaceuticals inc. (AMLX) PT Lowered to $8 at Deutsche Bank
-
Leerink Partners Downgrades Amylyx Pharmaceuticals inc. (AMLX) to Market Perform
-
Baird Downgrades Amylyx Pharmaceuticals inc. (AMLX) to Neutral
-
Goldman Sachs Downgrades Amylyx Pharmaceuticals inc. (AMLX) to Neutral
-
Goldman Sachs Downgrades Amylyx Pharmaceuticals inc. (AMLX) to Neutral
-
Evercore ISI Downgrades Amylyx Pharmaceuticals inc. (AMLX) to In Line
-
Amylyx (AMLX) Falls 70% After Phase 3 PHOENIX Trial of AMX0035 in ALS Did Not Meet Prespecified Primary or Secondary Endpoints
-
Amylyx Pharmaceuticals (AMLX) Announces Topline Results From Global Phase 3 PHOENIX Trial of AMX0035 in ALS
-
Amylyx Pharmaceuticals inc. (AMLX) PT Raised to $32 at Mizuho
-
Amylyx Pharmaceuticals, Inc. (AMLX) Misses Q4 EPS by 16c
-
Amylyx Pharmaceuticals (AMLX) June call spreaders active as share price up 4.4%
-
Baird Starts Amylyx Pharmaceuticals inc. (AMLX) at Outperform, 'we believe the stock could quadruple'
-
This pharma stock is a top pick for 2024
-
Amylyx Pharmaceuticals inc. (AMLX) PT Lowered to $27 at Mizuho Securities
-
These stocks have just been added to Deutsche Bank's Fresh Money List
-
Point72 Asset Management, L.P. Shows 5.1% Stake in Amylyx Pharmaceuticals (AMLX) - 13G
-
Deutsche Bank Starts Amylyx Pharmaceuticals inc. (AMLX) at Buy
-
Amylyx Pharmaceuticals (AMLX) Appoints Camille L. Bedrosian, MD, as Chief Medical Officer
-
Amylyx Pharmaceuticals inc. (AMLX) PT Lowered to $42 at H.C. Wainwright
-
Amylyx Pharmaceuticals inc. (AMLX) PT Lowered to $40 at Goldman Sachs
-
Amylyx Pharmaceuticals, Inc. (AMLX) Misses Q3 EPS by 14c
-
Amylyx Pharmaceuticals inc. (AMLX) PT Lowered to $46 at Mizuho Securities
-
Amylyx Pharmaceuticals (AMLX) Receives Negative CHMP Opinion on its MAA for AMX0035 for Treatment of ALS in the European Union Following Re-Examination Process
-
Amylyx Pharmaceuticals (AMLX) Announces Publication of Survival Analysis Comparing CENTAUR to Historical Clinical Trial Control
-
Amylyx Pharmaceuticals (AMLX) Provides Update on Accès Compassionnel for AMX0035 in France
-
Amylyx Pharmaceuticals, Inc. (AMLX) Tops Q2 EPS by 12c
-
Goldman Sachs Upgrades Amylyx Pharmaceuticals inc. (AMLX) to Buy, 'Expectations for PHOENIX failure appear overdone'
-
Amylyx Pharmaceuticals (AMLX) Receives CHMP Negative Opinion on its Conditional Marketing Authorisation Application for AMX0035 for the Treatment of ALS in the European Union
-
Amylyx Pharmaceuticals (AMLX) Completes Negotiation Process and Signs Letter of Intent with the pCPA for ALBRIOZA for the Treatment of ALS
-
Amylyx Pharmaceuticals (AMLX) Provides Update on Ongoing Regulatory Review of AMX0035 for the Treatment of ALS in the European Union
-
Amylyx Pharmaceuticals inc. (AMLX) PT Lowered to $50 at Mizuho Securities
-
Amylyx Pharmaceuticals inc. (AMLX) PT Lowered to $53 at Citi
-
After-hours movers: News Corp, Amylyx gain following earnings
-
Amylyx Pharmaceuticals stock surges 4% on Q1 beat
-
Amylyx Pharmaceuticals, Inc. (AMLX) Tops Q1 EPS by 29c
-
Mizuho Securities Starts Amylyx Pharmaceuticals inc. (AMLX) at Buy
-
Amylyx Pharmaceuticals inc. (AMLX) PT Raised to $47 at Goldman Sachs
-
Amylyx Pharmaceuticals inc. (AMLX) PT Raised to $47 at Goldman Sachs
-
Amylyx Pharmaceuticals (AMLX) Files Mixed Shelf
-
Amylyx Pharmaceuticals inc. (AMLX) PT Raised to $54 at Citi
-
After-hours movers: GitLab, UAL falls on lower guidance
-
Evercore's DiFiore on Amylyx Pharmaceuticals inc. (AMLX) ALS Relyvrio Launch: 'I feel very confident in launch and remain very constructive'
-
BofA Securities Starts Amylyx Pharmaceuticals inc. (AMLX) at Buy
-
Amylyx Pharmaceuticals inc. (AMLX) PT Raised to $51 at Citi
-
Amylyx Pharmaceuticals, Inc. (AMLX) Tops Q3 EPS by 1c
-
Amylyx Pharmaceuticals inc. (AMLX) PT Raised to $50 at H.C. Wainwright
-
Amylyx Pharmaceuticals (AMLX) Prices Upsized 6.69M Share Offering at $32/sh
Back to AMLX Stock Lookup